Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report

ABSTRACT

Hepatoid adenocarcinoma of the lung (HAL) is a rare and aggressive subtype of lung cancer. The prognosis for patients with HAL is generally poor and currently, there are only limited treatment options. Here, we present a case of a 47-year-old male diagnosed with locally advanced-stage HAL who achieved a remarkably long disease-free survival after receiving neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery. This case highlights the potential of immunochemotherapy plus surgery in improving outcomes for patients with HAL.

KEYWORDS:

• Hepatoid adenocarcinoma of the lung
• camrelizumab
• immunotherapeutics
• surgery
• survival

Disclosure statement

No potential conflict of interest was reported by the author(s).

Author contributions statement

Xuhua Huang: Conceptualization; Investigation; Methodology; Writing – original draft; Writing – review & editing. Linhai Zhu: Conceptualization; Investigation; Methodology; Writing – original draft. Weifeng Pan: Investigation; Validation. Jian Hu: Conceptualization; Funding acquisition; Investigation; Resources; Supervision; Writing – review & editing. All authors agree to be accountable for all aspects of the work.

Ethics statement

The Clinical Research Ethics Committee of the First Affiliated Hospital of Zhejiang University School of Medicine (FAHZU) approved the study (Grant No. IIT20230461A), and written informed consent was obtained before all the treatments from the patient.

Additional information

Funding

This research was supported by the National Key Research and Development Program of China [Grant number: 2022YFC2407303], Major Science and Technology Projects of Zhejiang Province [Grant number: 2020C03058], and Research Center for Lung Tumor Diagnosis and Treatment of Zhejiang Province [Grant number: JBZX-202007].